Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small share sale primarily tied to equity compensation. On common stock, he sold 2,409 shares in an open-market transaction at about $3.014 per share to pay tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
After this transaction, Shah directly holds 1,040,918 shares of common stock, and also reports indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that his holdings include RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported a small open-market sale of company common stock. He sold 662 shares on May 19, 2026 at an average price of $3.014 per share. Footnotes state the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units that convert into common stock on a one-for-one basis. After this transaction, he continues to hold 677,977 shares of common stock, indicating the sale represents a very small portion of his overall position.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported selling 384 shares of common stock at $3.014 per share on May 19, 2026. According to the footnotes, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this transaction, Militello directly holds 89,780 shares of common stock. The filing characterizes the trade as an open-market sale but clarifies that its purpose was to cover taxes related to equity compensation rather than a discretionary portfolio adjustment.
Rocket Pharmaceuticals files a Form 144 to sell 55,684 shares. The filing lists an intended sale of 55,684 shares of Common Stock via an option granted on 04/12/2017, with the sale dated 05/21/2026 for cash. The filing also discloses recent transfers: 2,728 shares sold on 05/13/2026 for $9,836.08 and 2,409 shares sold on 05/19/2026 for $7,261.69.
Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Form 144 notice reporting a proposed sale of 2,409 Common shares associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also discloses 2,728 Common shares sold during the prior three months on 05/13/2026.
RCKT filing a Form 144 notice reporting the sale or proposed sale of 384 shares of common stock associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also lists a prior sale of 855 shares on 05/13/2026.
RCKT submitted a Rule 144 notice covering 662 shares of Common Stock.
The filing states the 662 shares arose from Restricted Stock Vesting dated 05/15/2026. It also records a separate sale of 3,361 shares on 05/13/2026 with proceeds of $12,118.42.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported an open-market sale of 3,361 shares of common stock at $3.606 per share. The footnotes state the shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis. After this transaction, Wilson directly holds 678,639 shares, so the sale represents only a small portion of his overall position and appears tied to compensation-related taxes rather than a discretionary portfolio change.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small sale of common stock mainly tied to taxes on equity compensation. He sold 2,728 shares on May 13, 2026 at $3.606 per share to pay tax withholding obligations related to vesting restricted stock units.
After this sale, he directly holds 1,043,327 shares of common stock, with additional indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that these holdings include RSUs that convert one-for-one into common stock.